A detailed history of Bourne Lent Asset Management Inc transactions in Pfizer Inc stock. As of the latest transaction made, Bourne Lent Asset Management Inc holds 21,805 shares of PFE stock, worth $610,103. This represents 0.24% of its overall portfolio holdings.

Number of Shares
21,805
Previous 25,805 15.5%
Holding current value
$610,103
Previous $742,000 18.46%
% of portfolio
0.24%
Previous 0.3%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 12, 2024

SELL
$25.89 - $29.73 $103,560 - $118,920
-4,000 Reduced 15.5%
21,805 $605,000
Q4 2023

Jan 19, 2024

SELL
$26.13 - $33.94 $287,430 - $373,340
-11,000 Reduced 29.89%
25,805 $742,000
Q4 2022

Jan 23, 2023

SELL
$41.75 - $54.5 $49,014 - $63,983
-1,174 Reduced 3.09%
36,805 $0
Q2 2022

Jul 27, 2022

SELL
$46.53 - $55.17 $32,571 - $38,619
-700 Reduced 1.81%
37,979 $1.99 Million
Q1 2021

Apr 23, 2021

BUY
$33.49 - $37.77 $23,443 - $26,439
700 Added 1.84%
38,679 $1.4 Million
Q4 2020

Jan 27, 2021

BUY
$33.47 - $42.56 $368,170 - $468,160
11,000 Added 40.77%
37,979 $1.4 Million
Q1 2020

Apr 17, 2020

SELL
$27.03 - $38.62 $27,030 - $38,620
-1,000 Reduced 3.57%
26,979 $881,000
Q4 2019

Jan 24, 2020

SELL
$32.92 - $37.36 $104,685 - $118,804
-3,180 Reduced 10.21%
27,979 $1.1 Million
Q3 2019

Oct 24, 2019

SELL
$32.49 - $42.13 $16,245 - $21,065
-500 Reduced 1.58%
31,159 $1.12 Million
Q4 2018

Jan 28, 2019

SELL
$38.47 - $43.86 $73,477 - $83,772
-1,910 Reduced 5.69%
31,659 $1.38 Million
Q2 2018

Jul 25, 2018

BUY
$32.98 - $35.16 $5,936 - $6,328
180 Added 0.54%
33,569 $1.22 Million
Q1 2018

Apr 20, 2018

SELL
$31.91 - $37.02 $57,884 - $67,154
-1,814 Reduced 5.15%
33,389 $1.19 Million
Q3 2017

Oct 16, 2017

BUY
$31.0 - $34.15 $1.09 Million - $1.2 Million
35,203
35,203 $1.26 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $157B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Bourne Lent Asset Management Inc Portfolio

Follow Bourne Lent Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bourne Lent Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bourne Lent Asset Management Inc with notifications on news.